Toll-like Receptor and Antiphospholipid Mediated Thrombosis: in Vivo Studies

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2007 Jan 31

PMID 17261530

Citations 68

Authors

Silvia S Pierangeli

Mariano E Vega-Ostertag

Elena Raschi

Xiaowei Liu

Zurina Romay-Penabad

Valeria De Micheli

Monica Galli

Marco Moia

Angela Tincani

Maria Orietta Borghi

Tracy Nguyen-Oghalai

Pier Luigi Meroni

Affiliations

Soon will be listed here.

Abstract

Objective: A study was undertaken to investigate the in vivo pathogenic role of Toll-like receptor 4 (TLR-4) in the antiphospholipid syndrome (APS) by studying the thrombogenic antiphospholipid (aPL) activity in lipopolysaccharide (LPS) non-responsive (LPS-/-) mice and the association between tlr4 gene polymorphisms and APS in patients.

Methods: IgGs from two patients with APS, one with aPL negative systemic lupus erythematosus (SLE) and one with normal human serum (NHS), were evaluated for thrombosis, tissue factor (TF) activity and endothelial cell activation in LPS-/- mice displaying a tlr4 spontaneous mutation vs LPS responsive (LPS+/+) mice. Human tlr4 Asp299Gly and Thr399Ile polymorphisms were evaluated by allele-specific PCR in 110 patients with APS with arterial/venous thrombosis and in 220 controls of the same ethnic origin.

Results: IgG-APS produced significantly larger thrombi and more leucocytes (WBC) adhering to endothelial cells in the cremaster muscle microcirculation of LPS+/+ mice than IgG-NHS or aPL negative SLE-IgG. These effects were abrogated after absorption of the anti-beta(2)glycoprotein I activity by an affinity column. The two IgG-APS induced significantly smaller thrombi and fewer WBC adhering to endothelial cells in LPS-/- mice than in LPS+/+ mice. IgG-APS induced higher TF activity in carotid artery homogenates of LPS+/+ mice than in LPS-/- mice. The prevalence of Asp299Gly and Thr399Ile tlr4 polymorphisms was significantly lower than in controls.

Conclusions: These findings in LPS-/- mice and the reduction in the "protective" polymorphism in patients with APS with thrombosis suggest that TLR-4 is involved in the interaction of aPL with endothelial cells in vivo.

Citing Articles

Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome.

Feng W, Qiao J, Tan Y, Liu Q, Wang Q, Yang B Front Immunol. 2024; 15:1361519.

PMID: 39044818 PMC: 11263079. DOI: 10.3389/fimmu.2024.1361519.

An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation.

Ryan T, ONeill L Cells. 2023; 12(5).

PMID: 36899914 PMC: 10001161. DOI: 10.3390/cells12050778.

Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.

Knight J, Kanthi Y Semin Immunopathol. 2022; 44(3):347-362.

PMID: 35122116 PMC: 8816310. DOI: 10.1007/s00281-022-00916-w.

Therapeutic Potential and Immunomodulatory Role of Coenzyme Q and Its Analogues in Systemic Autoimmune Diseases.

Lopez-Pedrera C, Villalba J, Patino-Trives A, Luque-Tevar M, Barbarroja N, Aguirre M Antioxidants (Basel). 2021; 10(4).

PMID: 33924642 PMC: 8069673. DOI: 10.3390/antiox10040600.

OxLDL/β2GPI/anti‑β2GPI Ab complex induces inflammatory activation via the TLR4/NF‑κB pathway in HUVECs.

Zhang G, Cai Q, Zhou H, He C, Chen Y, Zhang P Mol Med Rep. 2020; 23(2).

PMID: 33355374 PMC: 7789093. DOI: 10.3892/mmr.2020.11787.

References

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Cook D, Pisetsky D, Schwartz D . Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004; 5(10):975-9. DOI: 10.1038/ni1116. View

McNeil H, Simpson R, Chesterman C, Krilis S . Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87(11):4120-4. PMC: 54059. DOI: 10.1073/pnas.87.11.4120. View

Galli M, Comfurius P, Maassen C, Hemker H, De Baets M, Barbui T . Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990; 335(8705):1544-7. DOI: 10.1016/0140-6736(90)91374-j. View

Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T . Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336(8708):177-8. DOI: 10.1016/0140-6736(90)91697-9. View

Simantov R, Lasala J, Lo S, Gharavi A, Sammaritano L, Salmon J . Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995; 96(5):2211-9. PMC: 185871. DOI: 10.1172/JCI118276. View

Pierangeli S, Liu X, Barker J, Anderson G, Harris E . Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995; 74(5):1361-7. View

Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, Cattaneo R . The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol. 1996; 157(12):5732-8. View

Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y . C5a induces tissue factor activity on endothelial cells. Thromb Haemost. 1997; 77(2):394-8. View

10.

Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta M, Ichikawa K . Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997; 40(3):551-61. DOI: 10.1002/art.1780400322. View

11.

Del Papa N, Sheng Y, Raschi E, Kandiah D, Tincani A, Khamashta M . Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol. 1998; 160(11):5572-8. View

12.

Pierangeli S, Colden-Stanfield M, Liu X, Barker J, Anderson G, Harris E . Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999; 99(15):1997-2002. DOI: 10.1161/01.cir.99.15.1997. View

13.

Girardi G, Redecha P, Salmon J . Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10(11):1222-6. DOI: 10.1038/nm1121. View

14.

Day S, Reeve J, Pedersen B, Farris D, Myers D, Im M . Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2004; 105(1):192-8. DOI: 10.1182/blood-2004-06-2225. View

15.

Kawai T, Akira S . Toll-like receptor downstream signaling. Arthritis Res Ther. 2005; 7(1):12-9. PMC: 1064894. DOI: 10.1186/ar1469. View

16.

Zhang J, McCrae K . Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2004; 105(5):1964-9. DOI: 10.1182/blood-2004-05-1708. View

17.

Schroder N, Schumann R . Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005; 5(3):156-64. DOI: 10.1016/S1473-3099(05)01308-3. View

18.

Kmonickova E, Zidek Z . Quantitative aspects of lipopolysaccharide and cytokine requirements to generate nitric oxide in macrophages from LPS-hyporesponsive (Lps(d)) C3H/HeJ mice. Folia Microbiol (Praha). 2005; 49(6):737-44. DOI: 10.1007/BF02931558. View

19.

Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris E, Pierangeli S . Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 2005; 52(5):1545-54. DOI: 10.1002/art.21009. View

20.

Rossignol D, Lynn M . TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs. 2005; 6(5):496-502. View